Zhiqiang Z Yang

US Patent:

20230105982, Apr 6, 2023

Filed:

Jul 28, 2021

Appl. No.:

17/386958

Inventors:

- Rahway NJ, US
Chunhui Huang - Arlington MA, US
Zhiqiang Yang - Westfield NJ, US
Lin Yan - East Brunswick NJ, US
Songnian Lin - Holmdel NJ, US
Pei Huo - Millburn NJ, US
Qiaolin Deng - Edison NJ, US
Elisabetta Bianchi - Pomezia, IT
Federica Orvieto - Pomezia, IT

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 47/62
A61K 38/26
A61K 38/28
A61K 47/54
A61P 3/08

Abstract:

Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.

US Patent:

20210163445, Jun 3, 2021

Filed:

Dec 10, 2018

Appl. No.:

16/770697

Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US

International Classification:

C07D 401/12
C07D 215/22
C07D 487/04
C07D 487/08
C07D 403/12

Abstract:

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

US Patent:

20200385386, Dec 10, 2020

Filed:

Oct 11, 2018

Appl. No.:

16/760790

Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US

International Classification:

C07D 471/22
C07D 487/22
C07D 498/22

Abstract:

The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

US Patent:

20200369667, Nov 26, 2020

Filed:

Nov 1, 2018

Appl. No.:

16/767077

Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US

International Classification:

C07D 487/04
C07D 519/00
C07H 19/14

Abstract:

The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMTS inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMTS associated disorders are also described.

US Patent:

20200239464, Jul 30, 2020

Filed:

Sep 5, 2018

Appl. No.:

16/648213

Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US

International Classification:

C07D 471/04
C07D 215/14
C07D 401/08
C07D 401/12
C07D 401/04

Abstract:

The present disclosure describes novel IDO inhibitors and methods for preparing them. The pharmaceutical compositions comprising such IDO inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described

US Patent:

20190307753, Oct 10, 2019

Filed:

May 11, 2017

Appl. No.:

16/301935

Inventors:

Alan WHITEHEAD - Kenilworth NJ, US
Olga ORNOSKI - Kenilworth NJ, US
Subharekha RAGHAVAN - Kenilworth NJ, US
Raphaelle BERGER - Kenilworth NJ, US
Joie GARFUNKLE - Kriens, CH
Zhiqiang YANG - Westfield NJ, US
Gang JI - Beijing, CN
Falong JIANG - Beijing, CN
Jianmin FU - Beijing, CN
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/519
C07D 519/00
A61P 9/12

Abstract:

The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, R, R, R, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceutical s for this purpose.

US Patent:

20190282579, Sep 19, 2019

Filed:

May 12, 2017

Appl. No.:

16/301936

Inventors:

- Rahway NJ, US
Guizhen Dong - Dayton NJ, US
Subharekha Raghavan - Teaneck NJ, US
Zhiqiang Yang - Westfield NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/519
A61K 45/06

Abstract:

Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R, R, R, R, and Rare as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy.

US Patent:

20190192675, Jun 27, 2019

Filed:

Apr 21, 2017

Appl. No.:

16/092155

Inventors:

- Rahway NJ, US
ZhiQiang YANG - Westfield NJ, US
Lin YAN - Kenilworth NJ, US
Songnian LIN - Kenilworth NJ, US
Pei HUO - Kenilworth NJ, US
Ravi NARGUND - Kenilworth NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 47/62
A61K 38/28
A61K 38/26
A61K 47/54
A61K 47/60

Abstract:

Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.